Coverage
Filings
| Filing | Date |
|---|---|
| Registration of capital increase completed | 26 Nov 2010 |
| Major shareholder announcement | 26 Nov 2010 |
| Zealand Pharma A/S publishes Financial Calendar for 2011 | 24 Nov 2010 |
| Zealand Pharma, Zealand Pharma withdraws IPO | 4 Dec 2005 |
| Zealand Pharma, announcement of prospectus | 25 Nov 2005 |
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.